Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study.
Détails
ID Serval
serval:BIB_F6DF3333A457
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study.
Périodique
European Journal of Gastroenterology and Hepatology
Collaborateur⸱rice⸱s
CheObs Study Group
Contributeur⸱rice⸱s
Alric L., Andreani T., Antoni M., Arpurt JP., Bacq Y., Bailly F., Balian A., Ballorain X., Bapin C., Barbare JC., Barbereau D., Bardou M., Baroni JL., Barriere E., Bary M., Bellaiche G., Bellon S., Benali S., Benhaim S., Beorchia S., Bernard P., Bernard-chabert B., Besson I., Bettan L., Beurton I., Bianchi D., Blanc P., Blanchi A., Bommelaer G., Bonaventure C., Bonny C., Bottafridlund D., Boulant J., Boulay G., Bourliere M., Boyer N., Bramli S., Bronowicki JP., Brung-lefebvre M., Calmus Y., Canva JY., Canvadelcambre V., Cassigneul J., Castera L., Causse X., Cayla JM., Chevalier C., Chevassus P., Chiari R., Chryssostalis A., Combis JM., Conti F., Corcos D., Croizet O., Cuillerier E., Czernichow B., D'Alteroche L., Danielou H., Danne O., Dao MT., D'Arondel De Haye C., Delasalle P., Deltenre P., Denis J., Dernaika S., Desmorat H., Doll J., Doumet S., Duclos-Vallee JC., Duffaut M., Elfadel S., Eschmann G., Eugene C., Faroux R., Fartoux Heymann L., Fatisse A., Filoche B., Fleury A., Fouchard-hubert I., Foucher J., Fratte S., Garcia V., Gargot D., Gaudin JL., Giuily N., Goria O., Gourlaouen A., Grimaldi S., Guillemard C., Guillygomarc'h A., Guyader D., Habersetzer F., Hachemane S., Haddad N., Hagege H., Haioun N., Hanslik B., Hatem C., Hemery ML., Hervio P., Hezode C., Hilleret£££Noëlle£££ N. , Hillon P., Hyrailles V., Jacques JP., Kitmacher P., Landau A., Lapoile E., Larrey D., Larroque O., Le Calvez S., Lebray P., Lejeune O., Lemoine A., Levy S., Longo F., Loustaud Ratti V., Louvet H., Lucidarme D., Mathieu-chandelier C., Mathurin P., Metivier S., Miguet JP., Minello A., Mion F., Moussalli J., Nalet B., Nousbaum JB., Oberti F., Oules V., Pageaux GP., Payen JL., Pilette C., Pillon D., Portal I., Pouderoux P., Raffanel C., Ramgoolam B., Randl K., Ratziu V., Regimbeau C., Remy AJ., Renou C., Riachi G., Ribard D., Ribiere O., Richardet JP., Ripault MP., Roche B., Roche C., Rogeaux O., Rollux R., Rosa I., Roudotthoraval F., Saliba F., Sapey T., Savary O., Scalone O., Schnee M., Schoeny M., Serfaty L., Serpaggi J., Sgro E., Si Ahmed SN. , Souvignet C., Szostak-talbodec N., Tellaroli JC., Thabut D., Tordjman G., Trepo C., Truchi R., Vanlemmens C., Vitte R., Zarski JP.
ISSN
1473-5687 (Electronic)
ISSN-L
0954-691X
Statut éditorial
Publié
Date de publication
2010
Volume
22
Numéro
9
Pages
1050-1057
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
OBJECTIVE: Injection drug users are often excluded from hepatitis C virus (HCV) treatment. This study compares sustained virological response, adherence, and quality of life in patients with or without a history of illicit drug use in routine clinical practice.
METHODS: This is a post-hoc analysis of a prospective, observational study conducted in 1860 patients who received peginterferon alpha-2b/ribavirin combination therapy. Nondrug users (NDUs) were defined as patients without a history of drug addiction; former drug users (FDUs) as patients who had stopped using illicit drugs or opioid maintenance therapy and active drug users (ADUs) as patients using illicit drugs or on opioid maintenance therapy. Virological response, adherence, and the health-related quality of life were assessed by the measure of HCV RNA in the serum, self-report and 36-item short-form health survey Questionnaire, respectively.
RESULTS: The analyzed population included 1038 (56%) NDUs, 578 (31%) FDUs, and 244 (13%) ADUs. About 85% of ADUs were on opioid maintenance therapy and 25% used illicit drugs. Although ADUs had a more chaotic lifestyle and more psychiatric disorders, sustained virological response of ADUs (58%) did not differ from that of NDUs (49%) and FDUs (51%) (P=0.133). Adherence rates were 39% in NDUs and FDUs, and 37% in ADUs (P=0.883). Health-related quality of life was improved in the three groups after the end of treatment.
CONCLUSION: Our study suggests that HCV therapy in ADUs on opioid maintenance therapy is as effective as in other HCV patients. The effectiveness of HCV therapy in illicit drug users needs to be evaluated in further studies.
METHODS: This is a post-hoc analysis of a prospective, observational study conducted in 1860 patients who received peginterferon alpha-2b/ribavirin combination therapy. Nondrug users (NDUs) were defined as patients without a history of drug addiction; former drug users (FDUs) as patients who had stopped using illicit drugs or opioid maintenance therapy and active drug users (ADUs) as patients using illicit drugs or on opioid maintenance therapy. Virological response, adherence, and the health-related quality of life were assessed by the measure of HCV RNA in the serum, self-report and 36-item short-form health survey Questionnaire, respectively.
RESULTS: The analyzed population included 1038 (56%) NDUs, 578 (31%) FDUs, and 244 (13%) ADUs. About 85% of ADUs were on opioid maintenance therapy and 25% used illicit drugs. Although ADUs had a more chaotic lifestyle and more psychiatric disorders, sustained virological response of ADUs (58%) did not differ from that of NDUs (49%) and FDUs (51%) (P=0.133). Adherence rates were 39% in NDUs and FDUs, and 37% in ADUs (P=0.883). Health-related quality of life was improved in the three groups after the end of treatment.
CONCLUSION: Our study suggests that HCV therapy in ADUs on opioid maintenance therapy is as effective as in other HCV patients. The effectiveness of HCV therapy in illicit drug users needs to be evaluated in further studies.
Mots-clé
Analgesics, Opioid/administration & dosage, Antiviral Agents/administration & dosage, Cohort Studies, Drug Therapy, Combination, Hepatitis C, Chronic/complications, Hepatitis C, Chronic/drug therapy, Interferon-alpha/administration & dosage, Medication Adherence, Polyethylene Glycols/administration & dosage, Prospective Studies, Quality of Life, Questionnaires, Recombinant Proteins, Ribavirin/administration & dosage, Substance-Related Disorders/complications, Substance-Related Disorders/drug therapy, Treatment Outcome
Pubmed
Web of science
Création de la notice
06/12/2013 10:10
Dernière modification de la notice
20/08/2019 16:23
Données d'usage
